Normal patterns and variants in single-photon emission computed tomography and positron emission tomography brain imaging

Seminars in Nuclear Medicine

Volumn 33, Issue 1, 2003, Pages 42-55

  Newberg, Andrew B ^a   Alavi, Abass ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 7 AMINO 8 IODOKETANSERIN; DIAMINE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODOPRIDE; KETANSERIN; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; N,N',N TRIMETHYL N' (2 HYDROXYL 3 METHYL 5 IODOBENZYL) 1,3 PROPANEDIAMINE I 123; QUINUCLIDINYL BENZILATE; SPIPERONE DERIVATIVE; UNCLASSIFIED DRUG;

BRAIN FUNCTION; BRAIN SCINTISCANNING; BRAIN TISSUE; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; FUNCTIONAL ASSESSMENT; HUMAN; LIFESPAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0037255516     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2003.127292     Document Type: Review

References (107)

1. Kuhl DE, Edwards RQ: Image separation of radioisotope scanning. Radiology 80:653-662, 1963
2. Kuhl DE, Edwards RQ, Ricci AR, et al: The MARK IV system for radionuclide computed tomography of the brain. Radiology 121:405-413, 1976
3. Alavi A, Hirsch LJ: Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography. Evolution over the past 2 decades. Semin Nucl Med 21:58-81, 1991
4. Diksic M, Reba RC (eds): Radiopharmaceuticals and Brain Pathology Studied With PET and SPECT. Boca Raton, FL, CRC Press. 1991
5. Kung HF: Overview of radiopharmaceuticals for diagnosis of central nervous disorders. Crit Rev Clin Lab Sci 28:269-286, 1991
6. 14C-2-deoxy-2-fluoro-D-glucose. J Label Comp Radiopharm 14:175-183, 1978
7. Ter-Pogossian MM, Phelps ME, Hoffman EJ, et al: A positron emission transaxial tomography for nuclear medicine imaging (PET). Radiology 114:89-98, 1975
8. Phelps ME, Hoffman EJ, Mullani NA, et al: Design considerations for a positron emission transaxial tomograph (PET-III). IEEE Trans Nucl Sci 23:516-522, 1976
9. Alavi A, Surti KS, Newberg A: Preliminary report of performance of high resolution gadalinium orthosilicate (GSO)-based dedicated brain PET scanner. J Nucl Med 29:296P, 2002
10. Newberg A, Alavi A, Reivich M: Detemination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med 32:13-34, 2002
11. Newberg AB, Alavi A, Payer F: Single photon emission computed tomography in Alzheimer's disease and related disorders, in George A (ed): Neuroimaging Clinics of North America, vol 5. Philadelphia, PA, WB Saunders Co, 1995, pp 103-123
12. 99Tcm-HMPAO-related changes in visual cortex can be detected with a single-head SPET system. Nucl Med Commun 17:480-484, 1996
13. Phelps ME, Mazziotta JC, Kuhl DE, et al: Tomographic mapping of human cerebral metabolism: Visual stimulation and deprivation. Neurol 31:517-529, 1981
14. Beer J, Blakemore C, Previc FH, et al: Areas of the human brain activated by ambient visual motion, indicating three kinds of selfmovement. Exp Brain Res 143:78-88, 2002
15. Castelli F, Happe F, Frith U, et al: Movement and mind: A functional imaging study of perception and interpretation of complex intentional movement patterns. Neuroimage 12:314-325, 2000
16. Mazziotta JC, Phelps ME: Human sensory stimulation and deprivation: Positron emission tomographic results and strategies. Ann Neurol 15:S50-S60, 1984 (suppl)
17. Halpern AR, Zatorre RJ: When that tune runs through your head: A PET investigation of auditory imagery for familiar melodies. Cereb Cortex 9:697-704, 1999
18. Greene JD, Sommerville RB, Nystrom LE, et al: An fMRI investigation of emotional engagement in moral judgment. Science 293:2105-2108, 2001
19. Coull JT. Frith CD: Differential activation of right superior parietal cortex and intraparietal sulcus by spatial and nonspatial attention. Neuroimage 8:176-187, 1998
20. Newberg A, Alavi A, Baime M, et al: The measurement of regional cerebral blood flow during the complex cognitive task of meditation: A preliminary SPECT study. Psychiatry Res 106:113-122, 2001
21. Pardo JV. Fox PT, Raichle ME: Localization of a human system for sustained attention by positron emission tomography. Nature 349:61-64, 1991
22. Vogt BA, Finch DM, Olson CR: Functional heterogeneity in cingulate cortex: The anterior executive and posterior evaluative regions. Cereb Cortex 2:435-443, 1992
23. Reiman EM, Lane RD, Ahern GL, et al: Neuroanatomical correlates of externally and internally generated human emotion. Am J Psychiatry 154:918-925, 1997
24. Phan KL, Wager T, Taylor SF, et al: Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI. Neuroimage 16:331-348, 2002
25. Liberzon I, Zubieta JK, Fig LM, et al: Mu-opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A 99:7084-7089, 2002
26. Van Heertum RL, Tikofsky RS: Functional Cerebral SPECT and PET Imaging. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, p 45
27. Booij J, Habraken JB, Bergmans P, et al: Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39:1879-1884, 1998
28. Ichise M, Ballinger JR, Vines D, et al: Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med 38:31-37, 1997
29. Chugani HT: Functional brain imaging in pediatrics. Pediatr Clin North Am 39:777-799, 1992
30. Altman DI, Volpe JJ: Positron emission tomography in newborn infants. Clin Perinatol 18:549-562, 1991
31. Chugani HT, Phelps ME, Mazziotta JC: Positron emission tomography study of human brain functional development. Ann Neurol 22:487-497, 1987
32. Chugani HT, Phelps ME: Maturational changes in cerebral function in infants determined by [18]FDG positron emission tomography. Science 231:840-843, 1986
33. Takahashi T, Shirane R, Sato S, et al: Developmental changes of cerebral blood flow and oxygen metabolism in children. Am J Neuroradiol 20:917-922, 1999
34. Kennedy C, Sokoloff L: An adaptation of the nitrous oxide method to the study of the cerebral circulation in children: Normal values for cerebral blood flow and cerebral metabolic rate in childhood. J Clin Invest 36:1130, 1957
35. 99mTc-HMPAO SPECT. Neuroradiology 40:428-434, 1998
36. Liu HG, Mountz JM, Inampudi C, et al: A semiquantitative cortical circumferential normalization method for clinical evaluation of rCBF brain SPECT. Clin Nucl Med 22:596-604, 1997
37. Leenders KL, Perani D, Lammertsma AA, et al: Cerebral blood flow, blood volume, and oxygen utilization - Normal values and effects of age. Brain 113:27-47, 1990
38. Mozley PD, Sadek AM, Alavi A, et al: Effects of aging on the cerebral distribution of technetium-99m hexamethylpropylene amine oxime in healthy humans. Eur J Nucl Med 24:754-761, 1997
39. 99mTc-d,1-HMPAO and SPECT of the brain in normal aging. J Cereb Blood Flow Metab 11:508-521, 1991
40. Pantano P, Baron JC, Lebrun-Grandie P, et al: Regional cerebral blood flow and oxygen consumption in human aging. Stroke 15:635-641, 1984
41. Martin AJ, Friston KJ, Colebatch JG, et al: Decreases in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab 11:684-689, 1991
42. Takada H, Nagata K, Hirata Y, et al: Age-related decline of cerebral oxygen metabolism in normal population detected with positron emission tomography. Neurol Res 14:128-131, 1992
43. Pagani M, Salmaso D, Jonsson C, et al: Regional cerebral blood flow as assessed by principal component analysis and (99m)Tc-HMPAO SPET in healthy subjects at rest: Normal distribution and effect of age and gender. Eur J Nucl Med Mol Imaging 29:67-75, 2002
44. 99mTc-ECD brain perfusion SPET: Variability, asymmetry and effects of age and gender in healthy adults. Eur J Nucl Med 28:873-887, 2001
45. Chawluk JB, Alavi A, Hurtig H, et al: Altered patterns of regional cerebral glucose metabolism in aging and dementia. J Cereb Blood Flow Metab 5: S121-S122, 1985
46. deLeon M, George A, Tomanelli J, et al: Positron emission tomography studies of normal aging, a replication of PET III and 18-FDG using PET IV and II-CDG. Neurobiol Aging 8:319-323, 1987
47. Chawluk JB, Alavi A, Dann R, et al: Positron emission tomography in aging and dementia. Effect of cerebral atrophy. J Nucl Med 28:431-437, 1987
48. Weiss D, Souder E, Alavi A, et al: Effects of normal aging on whole brain and regional glucose metabolism as assessed by F-18 positron emission tomography. J Nucl Med 31:771, 1990
49. Yoshii F, Barker WW, Chang JY, et al: Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J Cereb Blood Flow Metab 8:654-661, 1988
50. Kuhl DE, Metter EJ, Riege WH, et al: Effects of human aging on patterns of local cerebral glucose utilization determined by the 18-F fluorodeoxyglucose method. J Cereb Blood Flow Metab 2:163-171, 1982
51. Alavi A, Jolles PR, Jamieson DG, et al: Anatomic and functional changes of the brain in normal aging and dementia as demonstrated by MRI, CT, and PET. Nucl Med Ann 49-79, 1989
52. Loessner A, Alavi A, Lewandrowski KU, et al: Regional cerebral function determined by FDG-PET in healthy volunteers: Normal patterns and changes with age. J Nucl Med 36:1141-1149, 1995
53. Eberling JL, Nordahl TE, Kusubov N, et al: Reduced temporal lobe glucose metabolism in aging. J Neuroimaging 5:178-182, 1995
54. Alavi A, Chawluck JB, Hurtig H, et al: Determination of patterns of regional cerebral glucose metabolism in normal aging and dementia. J Nucl Med 26:P69, 1985
55. Miura SA, Shapiro MB, Grady CL, et al: Effects of gender on glucose utilization rates in healthy humans: A positron emission tomography study. J Neurosci Res 27:500-504, 1990
56. Kawachi T, Ishii K, Sakamoto S, et al: Gender differences in cerebral glucose metabolism: A PET study. J Neurol Sci 199:79-83, 2002
57. Kuhl DE, Metter EJ, Riege WH, et al: The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurol 15: S133-S137, 1984 (suppl)
58. Hawkins RA, Mazziotta JC, Phelps ME, et al: Cerebral glucose metabolism as a function of age in man: Influence of the rate constants in fluorodeoxyglucose. J Cereb Blood Flow Metab 3:250-253, 1983
59. Dastur DK: Cerebral blood flow and metabolism in normal human aging, pathological aging, and senile dementia. J Cereb Blood Flow Metab 5:1, 1985
60. Yamaguchi T, Kanno I, Nemura K, et al: Reduction in regional cerebral metabolic rate of oxygen during human aging. Stroke 17:1220, 1986
61. Frackowiak RSJ, Gibbs JM: Cerebral metabolism and blood flow in normal aging and pathological aging, in Pagistretti PL (ed): Functional Radionuclide Imaging of the Brain. New York, NY, Raven Press, 1983
62. Wahlund LO, Agartz I, Almqvist O, et al: The brain in healthy aged individuals. MR imaging. Radiology 174:675-679, 1990
63. Jernigan TL, Archibald SL, Berhow MT, et al: Cerebral structure on MRI, part I. Localization of age-related changes. Biol Psychiatry 29:55-67, 1991
64. Tanna NK, Kohn MI, Horwich DN, et al: Analysis of brain and cerebrospinal fluid volumes with MR imaging. Impact on PET data, correction for atrophy. Radiology 178:123-130, 1991
65. Gur RC, Mozley PD, Resnick SM, et al: Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. Proc Natl Acad Sci U S A 88:2845-2849, 1991
66. Clark C, Hayden M, Hollenberg S, et al: Controlling for cerebral atrophy in positron emission tomography data. J Cereb Blood Flow Metab 7:510-512, 1987
67. Schlageter NL, Horwitz B, Creasey H, et al: Relation of measured brain glucose utilization and cerebral atrophy in man. J Neurol Neurosurg Psychiatry 50:779-785, 1987
68. Chawluk JB, Dann R, Alavi A, et al: The effect of focal cerebral atrophy in positron emission tomographic studies of aging and dementia. Nucl Med Biol 17:797-804, 1990
69. Rinne JO, Lonnberg P, Marjamaki P: Age-dependent decline in human brain dopamine D1 and D2 response. Brain Res 508:349-352, 1990
70. Rinne JO: Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 404:162-168, 1987
71. Morgan DG, Marcusson JO, Nyberg P, et al: Divergent changes in D1 and D2 dopamine binding sites in human brain during aging. Neurobiol Aging 8:195-201, 1987
72. Wang Y, Chan GL, Holden JE, et al: Age-dependent decline of dopamine D1 receptors in human brain: A PET study. Synapse 30:56-61, 1998
73. Cordes M, Snow BJ, Cooper S, et al: Age-dependent decline of nigrostriatal dopaminergic function: A positron emission tomographic study of grandparents and their grandchildren. Ann Neurol 36:667-670, 1994
74. Bhatt MH, Snow BJ, Martin WRW, et al: Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 29:673-677, 1991
75. Martin WRW, Palmer MR, Patlak CS, et al: Nigrostriatal function in man studied with positron emission tomography. Ann Neurol 26:535-542, 1989
76. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 34:33-35, 1977
77. Gibb WRG, Lees AJ: Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. N Neurol Neurosurg Psychiatry 54:388-396, 1991
78. Inoue M, Suhara T. Sudo Y, et al: Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci 69:1079-1084, 2001
79. Kaasinen V, Kemppainen N, Nagren K, et al: Age-related loss of extrastriatal dopamine D(2)-like receptors in women. J Neurochem 81:1005-1010, 2002
80. Sawle GV, Colebatch JG, Shah A. et al: Striatal function in normal aging: Implications for Parkinson's disease. Ann Neurol 28:799-804, 1990
81. 18F]-DOPA uptake: Absence of an aging effect. J Cereb Blood Flow Metab 13:881-888, 1993
82. Vingerhoets FJG, Snow BJ, Schulzer MJ, et al: Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 35:18-24, 1994
83. 11C] raclopride. J Cereb Blood Flow Metab 13:310-314, 1993
84. 18F-N-methylspiroperidol. Psychiatry Res 67:11-16, 1996
85. 11C] raclopride. Ann N Y Acad Sci 695:81-85, 1993
86. Kaasinen V. Vilkman H, Hietala J, et al: Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 21:683-688. 2000
87. Suhara T. Fukuda H, Inoue O, et al: Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology 103:41-45, 1991
88. 11C] nomifensine and positron emission tomography: The effects of age and Parkinson's disease. Acta Neurol Scand 77:192-201, 1988
89. van Dyck CH, Seibyl JP. Malison RT. et al: Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 36:1175-1181, 1995
90. Severson JA. Marcusson JO. Osterburg HH, et al: 5-Hydroxytryptamine-sensitive 3H-imipramine binding of pro-tein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Res 425:137-145, 1987
91. Mozley PD, Acton PD, Barraclough ED, et al: Effects of age on dopamine transporters in healthy humans. J Nucl Med 40:1812-1817, 1999
92. Yamamoto M, Suhara T, Okubo Y, et al: Age-related decline of serotonin transporters in living human brain of healthy males. Life Sci 71:751-757, 2002
93. Kuikka JT, Tammela L, Bergstrom KA, et al: Effects of ageing on serotonin transporters in healthy females. Eur J Nucl Med 28:911-913, 2001
94. 11C]WAY-100635 and PET Neuropsychopharmacology 24:522-530, 2001
95. Meltzer C, Drevets WC. Price JC, et al: Gender-specific aging effects on the serotonin 1A receptor. Brain Res 895:9-17, 2001
96. 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: Influence of age and gender in healthy subjects. Eur J Nucl Med 25:1617-1622, 1998
97. Sheline YI, Mintun MA, Moerlein SM, et al: Greater loss of 5-HT(2A) receptors in midlife than in late life. Am J Psychiatry 159:430-435, 2002
98. Meltzer CC, Smith G, Price JC, et al: Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: Persistence of effect after partial volume correction. Brain Res 813:167-171, 1998
99. Kuhl DE, Minoshima S, Fessler JA, et al: In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40:399-410. 1996
100. Suhara T, Inoue O, Kobayashi K, et al: Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 149:225-228, 1993
101. Lee KS. Frey KA, Koeppe RA, et al: In vivo quantification of cerebral muscarinic receptors in normal human aging using positron emission tomography and [11C]tropanyl benzilate. J Cereb Blood Flow Metab 16:303-310, 1996
102. Dewey SL, Volkow ND. Logan J, et al: Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res 27:569-575, 1990
103. Fowler JS, Volkow ND, Wang GJ, et al: Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18:431-435, 1997
104. O'Tuama LA, Phillips PC, Smith QR, et al: L-Methionine uptake by human cerebral cortex. Maturation from infancy to old age. J Nucl Med 32:16, 1991
105. O'Tuama LA, Guilarte TR, Douglass KH, et al: Assessment of [11C]-L-methionine transport into the human brain. J Cerebr Blood Flow Metab 8:341-345, 1988
106. Koeppe RA, Mangner T, Betz AL, et al: Use of [11C] aminocyclohexane-carboxylate for the measurement of amino acid uptake and distribution volume in human brain. J Cerebr Blood Flow Metab 10:727-739, 1990
107. Ito H, Hatazawa J, Murakami M, et al: Aging effect on neutral amino acid transport at the blood-brain barrier measured with L-[2-18F]-Fluorophenylalanine and PET. J Nucl Med 35:1232-1237, 1995